Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Cox

Showing results (731-740 of 757) with videos related to

Pageof 76
Sort By:
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.
Vaccine|October 9, 2007
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy UgandansMichael A Eller, Leigh Anne Eller, Marc S Opollo, et al.
Data in Brief|March 17, 2016
Active site specificity profiling datasets of matrix metalloproteinases (MMPs) 1, 2, 3, 7, 8, 9, 12, 13 and 14Ulrich Eckhard, Pitter F Huesgen, Oliver Schilling, et al.
Nature Communications|October 31, 2022
Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysisYoshiharu Muto, Eryn E Dixon, Yasuhiro Yoshimura, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|September 27, 2015
Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analysesUlrich Eckhard, Pitter F Huesgen, Oliver Schilling, et al.
The Journal of Infectious Diseases|October 29, 2002
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cellsMary A Marovich, John R Mascola, Michael A Eller, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2024
Diamond surface functionalization via visible light-driven C-H activation for nanoscale quantum sensingLila V H Rodgers, Suong T Nguyen, James H Cox, et al.
Vaccine|January 12, 2012
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challengeJosephine H Cox, Maria G Ferrari, Patricia Earl, et al.
Pageof 76

Showing results (731-740 of 757) with videos related to

Sort By:
Pageof 76
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.
Vaccine|October 9, 2007
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy UgandansMichael A Eller, Leigh Anne Eller, Marc S Opollo, et al.
Data in Brief|March 17, 2016
Active site specificity profiling datasets of matrix metalloproteinases (MMPs) 1, 2, 3, 7, 8, 9, 12, 13 and 14Ulrich Eckhard, Pitter F Huesgen, Oliver Schilling, et al.
Nature Communications|October 31, 2022
Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysisYoshiharu Muto, Eryn E Dixon, Yasuhiro Yoshimura, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|September 27, 2015
Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analysesUlrich Eckhard, Pitter F Huesgen, Oliver Schilling, et al.
The Journal of Infectious Diseases|October 29, 2002
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cellsMary A Marovich, John R Mascola, Michael A Eller, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2024
Diamond surface functionalization via visible light-driven C-H activation for nanoscale quantum sensingLila V H Rodgers, Suong T Nguyen, James H Cox, et al.
Vaccine|January 12, 2012
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challengeJosephine H Cox, Maria G Ferrari, Patricia Earl, et al.
Pageof 76